Post-Bariatric Hypoglycemia
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
2100%
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
Amylyx PharmaceuticalsAvexitide
RecordatiPasireotide Diaspartate
Clinical Trials (2)
Total enrollment: 168 patients across 2 trials
Avexitide for Treatment of Post-Bariatric Hypoglycemia
Start: Apr 2025Est. completion: Oct 202675 patients
Phase 3Active Not Recruiting
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Start: Jan 2024Est. completion: Apr 202693 patients
Phase 2Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.